Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity

Seminars in Immunology

Volumn 22, Issue 3, 2010, Pages 144-154

  Speiser, Daniel E ^a   Romero, Pedro ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cancer immunotherapy; Immune suppressive mechanisms; Protective immune responses; T cell receptors; T cell vaccination

Indexed keywords

ABAGOVOMAB; AGATOLIMOD; ALUMINUM POTASSIUM SULFATE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; GLYCOPROTEIN GP 100 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; MELAN A; MELANOMA ANTIGEN 3; MICROSPHERE; MINERAL OIL; MONOCLONAL ANTIBODY; MONTANIDE ISA 51; MUCIN 1 VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NY ESO 1 ANTIGEN; ONCOPROTEIN; PEPTIDE VACCINE; PHOSPHORYL LIPID A; PLACEBO; PROVENGE; QS 21; SAPONIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS ANTIGEN; PEPTIDE; RECOMBINANT VACCINE;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EFFECTOR CELL; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MEMORY T LYMPHOCYTE; OVARY CARCINOMA; PROSTATE CARCINOMA; REVIEW; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY; IMMUNOTHERAPY; MICE; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 77953620919     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2010.03.004     Document Type: Review

References (185)

1. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450(7171):903-907.
2. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
3. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254(5038):1643-1647.
4. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26(32):5233-5239.
5. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008, 358(25):2698-2703.
6. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198(4):569-580.
7. Oka Y., Tsuboi A., Oji Y., Kawase I., Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008, 20(2):211-220.
8. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463(7278):191-196.
9. Simpson A.J. Sequence-based advances in the definition of cancer-associated gene mutations. Curr Opin Oncol 2009, 21(1):47-52.
10. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220:60-81.
11. Manicassamy S., Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 2009, 21(4):185-193.
12. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
13. Romero P., Cerottini J.C., Speiser D.E. The human T cell response to melanoma antigens. Adv Immunol 2006, 92:187-224.
14. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005, 175(9):6169-6176.
15. Walker E.B., Haley D., Miller W., Floyd K., Wisner K.P., Sanjuan N., et al. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res 2004, 10(2):668-680.
16. De Vries I.J., Bernsen M.R., van Geloof W.L., Scharenborg N.M., Lesterhuis W.J., Rombout P.D., et al. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother 2007, 56(10):1667-1676.
17. Slingluff C.L., Petroni G.R., Chianese-Bullock K.A., Smolkin M.E., Hibbitts S., Murphy C., et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007, 13(21):6386-6395.
18. Marrari A., Iero M., Pilla L., Villa S., Salvioni R., Valdagni R., et al. Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2007, 56(4):429-445.
19. Acres B., Limacher J.M. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005, 4(4):493-502.
20. Arlen P.M., Gulley J.L., Madan R.A., Hodge J.W., Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 2007, 27(5):451-462.
21. Tang C.K., Katsara M., Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008, 7(7):963-975.
22. Shumway N.M., Ibrahim N., Ponniah S., Peoples G.E., Murray J.L. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 2009, 23(5):277-287.
23. Tso C.L., Zisman A., Pantuck A., Calilliw R., Hernandez J.M., Paik S., et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 2001, 61(21):7925-7933.
24. Rezvani K. PR1 vaccination in myeloid malignancies. Expert Rev Vaccines 2008, 7(7):867-875.
25. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
26. Gnjatic S., Nishikawa H., Jungbluth A.A., Gure A.O., Ritter G., Jager E., et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006, 95:1-30.
27. Andersen M.H., Sorensen R.B., Schrama D., Svane I.M., Becker J.C., Thor Straten P. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 2008, 57(11):1735-1743.
28. Beatty G.L., Vonderheide R.H. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008, 7(7):881-887.
29. Connerotte T., Van Pel A., Godelaine D., Tartour E., Schuler-Thurner B., Lucas S., et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 2008, 68(10):3931-3940.
30. Coulie P.G., Karanikas V., Lurquin C., Colau D., Connerotte T., Hanagiri T., et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002, 188:33-42.
31. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005, 23(35):9008-9021.
32. Smith J.W., 2nd, Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T., et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003, 21(8):1562-1573.
33. Clay T.M., Custer M.C., McKee M.D., Parkhurst M., Robbins P.F., Kerstann K., et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999, 162(3):1749-1755.
34. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4(3):321-327.
35. Schwartzentruber DJ, Lawson D, Richards J, Cpnry RM, Miller D, Triesman J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma.. J Clin Oncol. 2009; 27(18s suppl):ASCO Annual Meeting, abstract CRA9011.
36. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997, 3(1):37-44.
37. Valmori D., Fonteneau J.F., Lizana C.M., Gervois N., Lienard D., Rimoldi D., et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998, 160(4):1750-1758.
38. Lienard D., Rimoldi D., Marchand M., Dietrich P.Y., van Baren N., Geldhof C., et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004, 4:4.
39. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115(3):739-746.
40. Speiser D.E., Baumgaertner P., Voelter V., Devevre E., Barbey C., Rufer N., et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008, 105(10):3849-3854.
41. Fourcade J., Kudela P., Andrade Filho P.A., Janjic B., Land S.R., Sander C., et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008, 31(8):781-791.
42. Karbach J., Gnjatic S., Bender A., Neumann A., Weidmann E., Yuan J., et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010, 126(4):909-918.
43. Baumgaertner P., Rufer N., Devevre E., Derre L., Rimoldi D., Geldhof C., et al. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res 2006, 66(4):1912-1916.
44. Chianese-Bullock K.A., Lewis S.T., Sherman N.E., Shannon J.D., Slingluff C.L. Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine 2009, 27(11):1764-1770.
45. Feyerabend S., Stevanovic S., Gouttefangeas C., Wernet D., Hennenlotter J., Bedke J., et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009, 69(9):917-927.
46. Gouttefangeas C., Stenzl A., Stevanovic S., Rammensee H.G. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007, 56(1):117-128.
47. Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002, 62(20):5818-5827.
48. Slingluff C.L., Petroni G.R., Olson W., Czarkowski A., Grosh W.W., Smolkin M., et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008, 26(30):4973-4980.
49. Babatz J., Rollig C., Lobel B., Folprecht G., Haack M., Gunther H., et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006, 55(3):268-276.
50. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61(17):6451-6458.
51. Berntsen A., Trepiakas R., Wenandy L., Geertsen P.F., thor Straten P., Andersen M.H., et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008, 31(8):771-780.
52. Curti A., Tosi P., Comoli P., Terragna C., Ferri E., Cellini C., et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 2007, 139(3):415-424.
53. Davis I.D., Chen Q., Morris L., Quirk J., Stanley M., Tavarnesi M.L., et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 2006, 29(5):499-511.
54. de Vries I.J., Bernsen M.R., Lesterhuis W.J., Scharenborg N.M., Strijk S.P., Gerritsen M.J., et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005, 23(24):5779-5787.
55. Hildenbrand B., Sauer B., Kalis O., Stoll C., Freudenberg M.A., Niedermann G., et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study. Prostate 2007, 67(5):500-508.
56. Kavanagh B., Ko A., Venook A., Margolin K., Zeh H., Lotze M., et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007, 30(7):762-772.
57. Lepisto A.J., Moser A.J., Zeh H., Lee K., Bartlett D., McKolanis J.R., et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008, 6(B):955-964.
58. Lesimple T., Neidhard E.M., Vignard V., Lefeuvre C., Adamski H., Labarriere N., et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 2006, 12(24):7380-7388.
59. Liu K.J., Wang C.C., Chen L.T., Cheng A.L., Lin D.T., Wu Y.C., et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004, 10(8):2645-2651.
60. Ribas A., Comin-Anduix B., Chmielowski B., Jalil J., de la Rocha P., McCannel T.A., et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009, 15(19):6267-6276.
61. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Brocker E.B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006, 17(4):563-570.
62. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195(10):1279-1288.
63. Slingluff C.L., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003, 21(21):4016-4026.
64. Svane I.M., Pedersen A.E., Johansen J.S., Johnsen H.E., Nielsen D., Kamby C., et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007, 56(9):1485-1499.
65. Tanaka F., Haraguchi N., Isikawa K., Inoue H., Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep 2008, 20(5):1111-1116.
66. Waeckerle-Men Y., Uetz-von Allmen E., Fopp M., von Moos R., Bohme C., Schmid H.P., et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006, 55(12):1524-1533.
67. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(16):3670-3679.
68. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24(19):3089-3094.
69. Pfisterer J., du Bois A., Sehouli J., Loibl S., Reinartz S., Reuss A., et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006, 17(10):1568-1577.
70. Sabbatini P., Dupont J., Aghajanian C., Derosa F., Poynor E., Anderson S., et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006, 12(18):5503-5510.
71. Neelapu S.S., Lee S.T., Qin H., Cha S.C., Woo A.F., Kwak L.W. Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 2006, 5(3):381-394.
72. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol. 2009; 27(18s):suppl; abstr 2.
73. Kruit W.H., van Ojik H.H., Brichard V.G., Escudier B., Dorval T., Dreno B., et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005, 117(4):596-604.
74. Atanackovic D., Altorki N.K., Stockert E., Williamson B., Jungbluth A.A., Ritter E., et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004, 172(5):3289-3296.
75. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003, 39(1):70-77.
76. Vansteenkiste J., Zielinski M., Linder A., Dahabre J., Esteban E., Malinowski W., et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007, 25(18s):7554.
77. Kruit WH, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). J Clin Oncol. 2008; 26. (May 20 suppl; abstr 9065).
78. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100(11):2014-2021.
79. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004, 101(29):10697-10702.
80. Nicholaou T., Ebert L.M., Davis I.D., McArthur G.A., Jackson H., Dimopoulos N., et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009, 15(6):2166-2173.
81. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007, 104(21):8947-8952.
82. Kawabata R., Wada H., Isobe M., Saika T., Sato S., Uenaka A., et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007, 120(10):2178-2184.
83. Uenaka A., Wada H., Isobe M., Saika T., Tsuji K., Sato E., et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immunity 2007, 7:9.
84. Adams S., O'Neill D.W., Nonaka D., Hardin E., Chiriboga L., Siu K., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008, 181(1):776-784.
85. Sharma P., Bajorin D.F., Jungbluth A.A., Herr H., Old L.J., Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008, 31(9):849-857.
86. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8(5):351-360.
87. Zhang H., Hong H., Li D., Ma S., Di Y., Stoten A., et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. J Biol Chem 2009, 284(14):9184-9191.
88. Sangha R., Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007, 13(15 Pt 2):s4652-4654.
89. Odunsi K., Qian F., Matsuzaki J., Mhawech-Fauceglia P., Andrews C., Hoffman E.W., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007, 104(31):12837-12842.
90. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008, 14(1):178-187.
91. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361(19):1838-1847.
92. Leffers N., Lambeck A.J., Gooden M.J., Hoogeboom B.N., Wolf R., Hamming I.E., et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009, 125(9):2104-2113.
93. Speetjens F.M., Kuppen P.J., Welters M.J., Essahsah F., Voet van den Brink A.M., Lantrua M.G., et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009, 15(3):1086-1095.
94. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
95. Jung T., Schauer U., Heusser C., Neumann C., Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993, 159(1-2):197-207.
96. Kearney E.R., Pape K.A., Loh D.Y., Jenkins M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994, 1(4):327-339.
97. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002, 8(6):631-637.
98. Czerkinsky C., Andersson G., Ekre H.P., Nillson L.A., Klareskog L., Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 1988, 110:29-36.
99. Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009, 6(7):520-526.
100. Newell E.W., Klein L.O., Yu W., Davis M.M. Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 2009, 6(7):497-499.
101. Price D.A., Brenchley J.M., Ruff L.E., Betts M.R., Hill B.J., Roederer M., et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 2005, 202(10):1349-1361.
102. Kedzierska K., La Gruta N.L., Davenport M.P., Turner S.J., Doherty P.C. Contribution of T cell receptor affinity to overall avidity for virus-specific CD8+ T cell responses. Proc Natl Acad Sci USA 2005, 102(32):11432-11437.
103. Speiser D.E. Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer. Curr Opin Immunol 2005, 17(4):419-422.
104. Rufer N. Molecular tracking of antigen-specific T-cell clones during immune responses. Curr Opin Immunol 2005, 17:441-447.
105. Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008, 14(6):623-628.
106. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 1981, 126:1614-1619.
107. Speiser D.E., Kyburz D., Stübi U., Hengartner H., Zinkernagel R.M. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities: low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide coated target cells but not for in vivo protection. J Immunol 1992, 149:972-980.
108. Alexander-Miller M.A., Leggatt G.R., Berzofsky J.A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996, 93(9):4102-4107.
109. Gallimore A., Dumrese T., Hengartner H., Zinkernagel R.M., Rammensee H.G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998, 187(10):1647-1657.
110. Yee C., Savage P.A., Lee P.P., Davis M.M., Greenberg P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999, 162:2227-2234.
111. Zeh H.J., 3rd, Perry-Lalley D., Dudley M.E., Rosenberg S.A., Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999, 162(2):989-994.
112. Derby M., Alexander-Miller M., Tse R., Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001, 166(3):1690-1697.
113. Messaoudi I., Guevara Patino J.A., Dyall R., LeMaoult J., Nikolich-Zugich J. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 2002, 298(5599):1797-1800.
114. Bennett M.S., Ng H.L., Dagarag M., Ali A., Yang O.O. Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 2007, 81(10):4973-4980.
115. Sedlik C., Dadaglio G., Saron M.F., Deriaud E., Rojas M., Casal S.I., et al. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 2000, 74(13):5769-5775.
116. Rizzuto G.A., Merghoub T., Hirschhorn-Cymerman D., Liu C., Lesokhin A.M., Sahawneh D., et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009, 206(4):849-866.
117. Speiser D.E., Baumgaertner P., Barbey C., Rubio-Godoy V., Moulin A., Corthesy P., et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006, 177(2):1338-1348.
118. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
119. Bendle G.M., Haanen J.B., Schumacher T.N. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol 2009, 21(2):209-214.
120. Miller R.A. The aging immune system: primer and prospectus. Science 1996, 273(5271):70-74.
121. Pawelec G., Akbar A., Caruso C., Effros R., Grubeck-Loebenstein B., Wikby A. Is immunosenescence infectious?. Trends Immunol 2004, 25(8):406-410.
122. Linton P.J., Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004, 5(2):133-139.
123. Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev 2005, 205:5-6.
124. Hadrup S.R., Strindhall J., Kollgaard T., Seremet T., Johansson B., Pawelec G., et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 2006, 176(4):2645-2653.
125. Lang A., Brien J.D., Messaoudi I., Nikolich-Zugich J. Age-related dysregulation of CD8+ T cell memory specific for a persistent virus is independent of viral replication. J Immunol 2008, 180(7):4848-4857.
126. Nikolich-Zugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 2008, 8:512-522.
127. Iancu E.M., Speiser D.E., Rufer N. Assessing ageing of individual T lymphocytes: mission impossible?. Mech Ageing Dev 2008, 129(1-2):67-78.
128. Ernst B., Lee D.S., Chang J.M., Sprent J., Surh C.D. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999, 11(2):173-181.
129. Nesic D., Vukmanovic S. MHC class I is required for peripheral accumulation of CD8+ thymic emigrants. J Immunol 1998, 160(8):3705-3712.
130. Touvrey C., Derre L., Devevre E., Corthesy P., Romero P., Rufer N., et al. Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. J Immunol 2009, 182(11):6718-6726.
131. Chattopadhyay P.K., Yu J., Roederer M. Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat Protoc 2006, 1(1):1-6.
132. Wehler T.C., Karg M., Distler E., Konur A., Nonn M., Meyer R.G., et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods 2008, 339(1):23-37.
133. Wolfl M., Kuball J., Ho W.Y., Nguyen H., Manley T.J., Bleakley M., et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110(1):201-210.
134. Krone B., Kolmel K.F., Grange J.M., Mastrangelo G., Henz B.M., Botev I.N., et al. Impact of vaccinations and infectious diseases on the risk of melanoma-evaluation of an EORTC case-control study. Eur J Cancer 2003, 39(16):2372-2378.
135. Mantovani A., Romero P., Palucka A.K., Marincola F.M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371(9614):771-783.
136. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008, 205(3):543-555.
137. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224(1):141-165.
138. McMahon C.W., Raulet D.H. Expression and function of NK cell receptors in CD8+ T cells. Curr Opin Immunol 2001, 13(4):465-470.
139. Speiser D.E., Pittet M.J., Valmori D., Dunbar R., Rimoldi D., Liénard D., et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 1999, 190(6):775-782.
140. Triebel F., Jitsukawa S., Baixeras E., Roman-Roman S., Genevee C., Viegas-Pequignot E., et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990, 171(5):1393-1405.
141. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10(1):29-37.
142. Murphy K.M., Nelson C.A., Sedy J.R. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 2006, 6(9):671-681.
143. Sedy J.R., Gavrieli M., Potter K.G., Hurchla M.A., Lindsley R.C., Hildner K., et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005, 6(1):90-98.
144. Watanabe N., Gavrieli M., Sedy J.R., Yang J., Fallarino F., Loftin S.K., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003, 4(7):670-679.
145. Liu X., Alexiou M., Martin-Orozco N., Chung Y., Nurieva R.I., Ma L., et al. Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol 2009, 182(8):4516-4520.
146. Sun Y., Brown N.K., Ruddy M.J., Miller M.L., Lee Y., Wang Y., et al. B and T lymphocyte attenuator tempers early infection immunity. J Immunol 2009, 183(3):1946-1951.
147. Okano M., Otsuki N., Azuma M., Fujiwara T., Kariya S., Sugata Y., et al. Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis. Clin Exp Allergy 2008, 38(12):1891-1900.
148. Derre L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010, 120(1):157-167.
149. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22(3):329-341.
150. Fritzsching B., Oberle N., Pauly E., Geffers R., Buer J., Poschl J., et al. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006, 108(10):3371-3378.
151. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6(4):295-307.
152. Jandus C., Bioley G., Dojcinovic D., Derre L., Baitsch L., Wieckowski S., et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 2009, 69(20):8085-8093.
153. Bricard G., Cesson V., Devevre E., Bouzourene H., Barbey C., Rufer N., et al. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009, 182(8):5140-5151.
154. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(3):162-174.
155. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182(8):4499-4506.
156. Schreiber H. Fundamental immunology 2003, 1557-1591. Lippincott Williams & Wilkins, Baltimore. W.E. Paul (Ed.).
157. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5(4):263-274.
158. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25(18):2546-2553.
159. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161.
160. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009, 182(10):6562-6568.
161. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9(10):1269-1274.
162. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64(16):5839-5849.
163. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005, 201(8):1257-1268.
164. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005, 202(7):931-939.
165. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001, 11(4):173-186.
166. Rutschman R., Lang R., Hesse M., Ihle J.N., Wynn T.A., Murray P.J. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol 2001, 166(4):2173-2177.
167. Beck C., Schreiber K., Schreiber H., Rowley D.A. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol 2003, 33(1):19-28.
168. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198(11):1741-1752.
169. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
170. Bachmann M.F., Kohler G., Ecabert B., Mak T.W., Kopf M. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 1999, 163(3):1128-1131.
171. Dejean A.S., Beisner D.R., Ch'en I.L., Kerdiles Y.M., Babour A., Arden K.C., et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009, 10(5):504-513.
172. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002, 3(11):1097-1101.
173. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11(1):7-13.
174. Wolchok J.D., Hoos A., O'Day S., Weber J.S., Hamid O., Lebbe C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23):7412-7420.
175. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007, 30(1):1-15.
176. Britten C.M., Janetzki S., Ben-Porat L., Clay T.M., Kalos M., Maecker H., et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009, 58(10):1701-1713.
177. Britten C.M., Janetzki S., van der Burg S.H., Gouttefangeas C., Hoos A. Toward the harmonization of immune monitoring in clinical trials: quo vadis?. Cancer Immunol Immunother 2008, 57(3):285-288.
178. Janetzki S., Price L., Britten C.M., van der Burg S.H., Caterini J., Currier J.R., et al. Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother 2009.
179. Janetzki S., Britten C.M., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., et al. MIATA" -minimal information about T cell assays. Immunity 2009, 31(4):527-528.
180. Clements C.J., Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002, 20(Suppl 3):S24-33.
181. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995, 6:277-296.
182. Brandenburg K., Wiese A. Endotoxins: relationships between structure, function, and activity. Curr Top Med Chem 2004, 4(11):1127-1146.
183. Kenney R.T., Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003, 2(2):167-188.
184. Kensil C.R., Wu J.Y., Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 1995, 6:525-541.
185. Pearse M.J., Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57(3):465-474.